Hemostemix Inc. (CVE:HEM – Get Free Report) rose 25% during mid-day trading on Friday . The company traded as high as C$0.08 and last traded at C$0.08. Approximately 101,000 shares were traded during trading, an increase of 3% from the average daily volume of 98,140 shares. The stock had previously closed at C$0.06.
Hemostemix Stock Performance
The stock’s fifty day moving average price is C$0.07 and its 200-day moving average price is C$0.06. The firm has a market cap of C$5.23 million, a price-to-earnings ratio of -3.00 and a beta of 0.15.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- What is a Low P/E Ratio and What Does it Tell Investors?
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- Why Invest in High-Yield Dividend Stocks?
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- How to Effectively Use the MarketBeat Ratings Screener
- MarketBeat Week in Review – 10/7 – 10/11
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
